Announcement • Jun 18
Adia Med Introduces Advanced Ultrasound-Guided IV Training Using Butterfly Portable Ultrasound Device Adia Med, the regenerative medicine and advanced IV therapy division of Adia Nutrition Inc. announced a major step forward in patient care quality. The company's Advanced Practice Registered Nurses (APRNs) and Registered Nurses (RNs) will be trained in ultrasound-guided intravenous (IV) insertions and administrations using the Butterfly portable ultrasound device. This specialized training will significantly enhance the precision and reliability of IV placements, leading to better therapeutic outcomes and a dramatically improved experience for patients - especially those with difficult-to-access veins caused by dehydration, chronic conditions, obesity, aging, or other factors. The hands-on training will allow Adia Med's clinical team to perform more accurate IV insertions for the company's advanced regenerative and nutrient therapies, including proprietary stem cell and exosome protocols, glutathione IV treatments, and other precision wellness infusions. Patients who previously struggled with traditional IV access will now enjoy faster, gentler, and more reliable procedures. The Butterfly portable ultrasound brings hospital-grade imaging to the point of care, allowing nurses to clearly visualize veins in real time. This technology is proven to increase insertion success rates, minimize multiple needle attempts, and create a more comfortable experience for patients. This initiative further strengthens Adia Med's position as a leader in innovative, patient-centered regenerative therapies. Announcement • Jan 08
Adia Nutrition, Inc. Appoints Dawn Bell as Chief Revenue Officer Adia Nutrition, Inc. announced the appointment of Dawn Bell as Chief Revenue Officer (CRO) through its subsidiary, ADIA Labs. Ms. Bell brings more than 15 years of proven expertise as a sales strategist in the medical device and pharmaceutical industries, with a strong history of driving growth and building successful partnerships. While Ms. Bell's role includes strengthening revenue for ADIA Nutrition and its laboratory operations, her primary contribution will be ensuring shared success across the entire ecosystem. She will be partnering with doctors and clinics to significantly increase their revenue by providing hands-on guidance and proven strategies to seamlessly integrate the Company's advanced regenerative therapies and diagnostic services into their practices-whether in regenerative medicine, orthopedics, pain management, wellness, or other specialties. This appointment comes at an important time as Adia Med of Winter Park prepares to launch its first Institutional Review Board (IRB)-approved clinical study focused on autism, marking a significant advancement in the Company's clinical and scientific efforts. Announcement • Oct 22
Adia Nutrition, Inc. Appoints Evan Thomas as Independent Medical Director for Its Medical Division, Adia Med Adia Nutrition, Inc. announced the appointment of Evan Thomas, MD, PhD, as an Independent Medical Director for its medical division, Adia Med. A renowned radiation oncologist and visionary, Dr. Thomas will oversee clinic practices, including the cutting-edge Autologous Hematopoietic Stem Cell Transplantation (AHSCT) program, finalizing protocols to prepare for patient intake once in-network provider status is secured with major insurers. Based in Winter Park, FL, Dr. Thomas serves as Chief Medical Officer of the Renaissance Institute of Precision Oncology &Radiosurgery. He is celebrated for his expertise in central nervous system (CNS) and functional radiosurgery, utilizing stereotactic radiosurgery (SRS) and stereotactic body radiotherapy (SBRT) to treat complex conditions. Dr. Thomas has pioneered Joint Glow, a therapy utilizing advanced radiotherapy for joint disorders, an innovative approach rare among U.S. physicians. His global influence includes clinical trial leadership, peer-reviewed publications, and lectures in over 15 countries. As Medical Director, Dr. Thomas will guide Adia Med's clinical operations, finalize AHSCT protocols, and oversee Adia Med's other specialized therapies ensuring exceptional patient care. 
